收费全文 | 22912篇 |
免费 | 1244篇 |
国内免费 | 260篇 |
医药卫生 | 24416篇 |
2023年 | 172篇 |
2022年 | 173篇 |
2021年 | 651篇 |
2020年 | 451篇 |
2019年 | 532篇 |
2018年 | 706篇 |
2017年 | 570篇 |
2016年 | 651篇 |
2015年 | 727篇 |
2014年 | 948篇 |
2013年 | 1149篇 |
2012年 | 1817篇 |
2011年 | 1827篇 |
2010年 | 1034篇 |
2009年 | 1009篇 |
2008年 | 1650篇 |
2007年 | 1624篇 |
2006年 | 1475篇 |
2005年 | 1401篇 |
2004年 | 1370篇 |
2003年 | 1236篇 |
2002年 | 1081篇 |
2001年 | 161篇 |
2000年 | 136篇 |
1999年 | 165篇 |
1998年 | 152篇 |
1997年 | 123篇 |
1996年 | 132篇 |
1995年 | 131篇 |
1994年 | 85篇 |
1993年 | 95篇 |
1992年 | 102篇 |
1991年 | 79篇 |
1990年 | 66篇 |
1989年 | 80篇 |
1988年 | 60篇 |
1987年 | 67篇 |
1986年 | 57篇 |
1985年 | 44篇 |
1984年 | 57篇 |
1983年 | 53篇 |
1982年 | 36篇 |
1981年 | 42篇 |
1980年 | 44篇 |
1979年 | 22篇 |
1978年 | 15篇 |
1977年 | 21篇 |
1976年 | 16篇 |
1974年 | 20篇 |
1971年 | 9篇 |
Areas covered: This review summarizes the mechanisms of action, current role and future directions of microtubule targeting agents; we focus on investigational agents in phase I and II clinical trials.
Expert opinion: Chemotherapy maintains a pivotal role in the treatment of NSCLC. New generation agents that have the potential to overcome the mechanisms of resistance to the available drugs may provide new therapeutic opportunities. Predictive biomarkers derived from combination strategies and phase III studies are necessary going forward. 相似文献
Background
Scientific guidelines consider atrial fibrillation (AF) complicating degenerative mitral regurgitation (DMR) a debated indication for surgery.Objectives
This study analyzed the prognostic/therapeutic implications of AF at DMR diagnosis and long-term.Methods
Patients were enrolled in the MIDA (Mitral Regurgitation International Database) registry, which reported the consecutive, multicenter, international experience with DMR due to flail leaflets echocardiographically diagnosed.Results
Among 2,425 patients (age 67 ± 13 years; 71% male, 67% asymptomatic, ejection fraction 64 ± 10%), 1,646 presented at diagnosis with sinus rhythm (SR), 317 with paroxysmal AD, and 462 with persistent AF. Underlying clinical/instrumental characteristics progressively worsened from SR to paroxysmal to persistent AF. During follow-up, paroxysmal and persistent AF were associated with excess mortality (10-year survival in SR and in paroxysmal and persistent AF was 74 ± 1%, 59 ± 3%, and 46 ± 2%, respectively; p < 0.0001), that persisted 20 years post-diagnosis and independently of all baseline characteristics (p values <0.0001). Surgery (n = 1,889, repair 88%) was associated with better survival versus medical management, regardless of all baseline characteristics and rhythm (adjusted hazard ratio: 0.26; 95% confidence interval: 0.23 to 0.30; p < 0.0001) but post-surgical outcome remained affected by AF (10-year post-surgical survival in SR and in paroxysmal and persistent AF was 82 ± 1%, 70 ± 4%, and 57 ± 3%, respectively; p < 0.0001).Conclusions
AF is a frequent occurrence at DMR diagnosis. Although AF is associated with older age and more severe presentation of DMR, it is independently associated with excess mortality long-term after diagnosis. Surgery is followed by improved survival in each cardiac rhythm subset, but persistence of excess risk is observed for each type of AF. Our study indicates that detection of AF, even paroxysmal, should trigger prompt consideration for surgery. 相似文献Areas covered: In this review, the evolution of the knowledge on INSTIs use in the clinical setting is reviewed, analyzed, and interpreted. Emphasis is placed on the properties possibly accounting for several superiority results achieved by INSTIs in non-inferiority designed comparative clinical trials, which led to their inclusion as first line options in all versions of HIV therapeutic guidelines.
Expert commentary: Some unprecedented clinical-pharmacological properties of INSTIs, such as their rapid and sustained action against HIV replication, the optimal tolerability and safety profile and a clinically proven robust genetic barrier are the main factors justifying the successful clinical use of INSTIs. Based on these unique features, novel INSTIs-based treatment modalities are being developed, including the reduction of antiretroviral regimens to two drugs only. 相似文献